DEERFIELD, Ill.–(BUSINESS WIRE)–For the fifth straight year, patient groups ranked Lundbeck US, an affiliate of the global pharmaceutical company H. Lundbeck A/S, #1 in corporate reputation. According to the new PatientView Corporate Reputation of Pharma, USA Edition, Lundbeck ranked 1st overall among leading pharmaceutical companies, as judged by U.S.-based patient groups that work or partner with the company.
“At Lundbeck, patient-centricity defines our culture, and we are honored that our patient-group partners recognize our authentic commitment,” said Peter Anastasiou, executive vice president and head of Lundbeck North America. “As the only global biopharmaceutical company solely focused on brain diseases, we are deeply committed to understanding the complex needs of our patient communities. Our patient-group partners are critical to our ability to deliver therapies and programs that will be most meaningful to people impacted by brain diseases, and we are grateful for their trust and ongoing collaboration.”
The PatientView report, which is based on a survey of 186 U.S. patient groups, compiles feedback on the performance of pharmaceutical companies on key indicators of corporate reputation. In addition to awarding the overall #1 ranking, patient groups that have worked or partnered with Lundbeck also ranked the company #1 in these nine individual reputational categories:
- Patient information
- Patient safety
- High-quality products
- Transparency in clinical data
- Corporate integrity
- Quality of patient-group relationships
- “Beyond the pill” services
- Engaging patients in development
In 2019, Lundbeck partnered with 33 different patient groups, and the company’s approximately 900 U.S. employees participated in nearly 400 patient advocacy events across the country. “Colleagues at every level and within every department of our organization embrace the opportunity to connect with our patient communities,” Anastasiou said. “These regular touchpoints allow us to hear directly from the people we serve and grants us better understanding of the needs of patients and their care partners.”
Novel patient-group collaborations
Lundbeck also regularly engages with patient groups in more organized ways, convening representatives of patient communities to gain insights into gaps in treatment, educational resources and community support. Highlights from the past year include:
Facilitating collaboration within the Parkinson’s community
Lundbeck again invited patient-group representatives to collaborate on meeting the needs of people affected by neurogenic orthostatic hypotension (nOH), a nervous system condition that can occur in people with Parkinson’s disease and multiple system atrophy. The nOH Advocacy Working Group, which Lundbeck first convened in 2015, represents the first time the various organizations have joined forces on patient initiatives.
In 2019, the company also collaborated with patient-group partners to expand Sidekicks®, an intergenerational program that brings together youth and people with Parkinson’s to learn from one another in a series of creative workshops. Sidekicks is offered by Lundbeck and the Davis Phinney Foundation in collaboration with other national Parkinson’s-focused patient organizations, and last year the program expanded to 10 markets and added digital programming for those who can’t participate in person.
Putting mental health patients at the center of drug development
Lundbeck recognizes that in order to achieve better outcomes for people living with mental health disorders, industry and regulators must understand and validate what outcomes matter most to patients themselves. The company collaborated with mental health patient groups on a variety of efforts to advance patient-centered drug development, including programs to involve regulators in discussions around patient-focused outcomes in mental health drug development.
Answering epilepsy community’s call to action
At the request of a long-time patient-group partner, Lundbeck completed the work needed to obtain a label expansion for a medicine used to treat a type of rare seizure disorder in children. Lundbeck enthusiastically took on the expense and effort of the label expansion knowing its importance to the patient community, despite facing multiple generic competitors that would mean little, if any, financial benefit to the company.
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global biopharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
Our approximately 6,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France and Italy.
In the U.S., Lundbeck employs approximately 900 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in a broad range of initiatives each year that support our patient communities.